Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Financing Activities (2019 - 2025)

BridgeBio Pharma's Cash from Financing Activities history spans 7 years, with the latest figure at -$2.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 100.46% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $359.3 million, down 52.0%, while the annual FY2025 figure was $359.3 million, 52.0% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$2.2 million at BridgeBio Pharma, down from -$894000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $547.9 million in Q1 2021 and bottomed at -$135.5 million in Q3 2021.
  • The 5-year median for Cash from Financing Activities is $1.1 million (2022), against an average of $114.1 million.
  • The largest annual shift saw Cash from Financing Activities crashed 4969.02% in 2021 before it soared 94005.62% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $325.4 million in 2021, then tumbled by 98.04% to $6.4 million in 2022, then plummeted by 170.93% to -$4.5 million in 2023, then soared by 10578.24% to $473.9 million in 2024, then plummeted by 100.46% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cash from Financing Activities are -$2.2 million (Q4 2025), -$894000.0 (Q3 2025), and $302.0 million (Q2 2025).